Title |
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
|
---|---|
Published in |
Journal of Cancer Research and Clinical Oncology, May 2014
|
DOI | 10.1007/s00432-014-1678-3 |
Pubmed ID | |
Authors |
J. C. von Einem, V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. G. Hass, T. Decker, S. Klein, S. Held, A. Jung, T. Kirchner, M. Haas, J. Holch, M. Michl, P. Aubele, S. Boeck, C. Schulz, C. Giessen, S. Stintzing, D. P. Modest |
Abstract |
AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the impact of primary tumor location on outcome of patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 1% |
Ecuador | 1 | 1% |
Unknown | 92 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 24 | 26% |
Other | 13 | 14% |
Student > Master | 10 | 11% |
Student > Ph. D. Student | 9 | 10% |
Student > Bachelor | 6 | 6% |
Other | 17 | 18% |
Unknown | 15 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 49 | 52% |
Biochemistry, Genetics and Molecular Biology | 10 | 11% |
Agricultural and Biological Sciences | 4 | 4% |
Nursing and Health Professions | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Other | 8 | 9% |
Unknown | 17 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2020.
All research outputs
#7,325,024
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#534
of 2,632 outputs
Outputs of similar age
#68,349
of 228,632 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#8
of 34 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,632 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.